Wednesday, August 13, 2008
To all health activists who demonize innovators or patent holders for allegedly pricing essential drugs beyond the reach of poor patients, the latest blunder with South African ARV generic manufacturer, Adcock Ingram might cause a rethink and appreciation of the extraordinary lengths big pharma goes to ensure efficacy of their drugs . Do not get us wrong. We are not saying producing generics are bad, in so far as a license is fairly procured and the potency of end product is assured.
